Novo Nordisk A/S saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month, after steep price cuts boosted demand for its branded treatments even as generic GLP-1 therapies flood the market.

Sales of Wegovy, Ozempic and partner-branded versions rose to 32,000 units in April, according to market researcher Pharmarack, marking the first full month of data since generic semaglutide started selling in India. Novo Nordisk slashed starting-dose prices by 36% and 48%, respectively, from April 1, bringing both drugs down to 5,660 rupees ($60).